Xerox: Looking To Get Long Post An Encouraging Q1 Report
https://seekingalpha.com/article/4684623-xerox-looking-to-get-long-post-encouraging-q1-earnings?source=feed_all_articles
Apr 18, 2024 - Xerox's profitability rises by over 12%, positive technical trends indicate potential bottoming pattern, and high dividend yield of 6.17%. See more on XRX stock.
0
Danaher (DHR) Gears Up to Post Q1 Earnings: Is a Beat Likely?
https://www.zacks.com/stock/news/2257902/danaher-dhr-gears-up-to-post-q1-earnings-is-a-beat-likely?cid=CS-ZC-FT-analyst_blog|earnings_preview-2257902
Apr 18, 2024 - Danaher's (DHR) Q1 earnings are likely to be hurt by weakness in the Biotechnology unit. Improving supply chains and strong price realization are expected to be positives.
0
NextEra Energy (NEE) to Post Q1 Earnings: What's in Store?
https://www.zacks.com/stock/news/2257828/nextera-energy-nee-to-post-q1-earnings-what-s-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2257828
Apr 18, 2024 - NextEra Energy (NEE) is likely to come out with an earnings surprise this season courtesy of strong performance of its segments and demand from expanding customer base.
0
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
https://www.zacks.com/stock/news/2257798/diamedica-dmac-up-as-stroke-study-dosing-begins-post-relaunch?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2257798
Apr 18, 2024 - DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.
0
Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?
https://www.zacks.com/stock/news/2257849/bio-rad-laboratories-bio-to-post-q1-earnings-what-awaits?cid=CS-ZC-FT-analyst_blog|earnings_preview-2257849
Apr 18, 2024 - The ongoing weakness in the biopharma end markets and tightening of sanctions against Russia is likely to have hurt Bio-Rad's (BIO) first-quarter 2024 growth.
0
Alexandria (ARE) to Post Q1 Earnings: What's in the Cards?
https://www.zacks.com/stock/news/2257051/alexandria-are-to-post-q1-earnings-what-s-in-the-cards?cid=CS-ZC-FT-analyst_blog|earnings_preview-2257051
Apr 17, 2024 - While Alexandria's (ARE) Q1 earnings are likely to have benefited from the healthy demand for its high-quality life science and lab office properties, high interest expenses raise concern.
0
Post Holdings (POST) Gains on Favorable Pricing & Brand Strength
https://www.zacks.com/stock/news/2257024/post-holdings-post-gains-on-favorable-pricing-brand-strength?cid=CS-ZC-FT-analyst_blog|rank_focused-2257024
Apr 17, 2024 - Post Holdings (POST) has been benefiting from strategic pricing actions undertaken to counter inflationary headwinds. Management is strengthening its business on the back of strategic acquisitions.
0
Clene stock rallies 52% post-market on MS drug data
https://seekingalpha.com/news/4090283-clene-stock-rallies-post-market-on-ms-drug-data?source=feed_sector_healthcare
Apr 16, 2024 - Clene (CLNN) stock rallied 52% post-market Tuesday after the company presented positive Phase 2 data for its drug CNM-Au8 in the treatment of multiple sclerosis. Read more here.
0
Align Technology (ALGN) to Post Q1 Earnings: What's in Store?
https://www.zacks.com/stock/news/2256315/align-technology-algn-to-post-q1-earnings-what-s-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2256315
Apr 16, 2024 - Align Technology's (ALGN) first-quarter 2024 performance is likely to reflect the strength of the Clear Aligner and Systems & Services businesses.
0
Netflix and United Airlines to report highest move post earnings: BofA
https://seekingalpha.com/news/4089597-bofa-picks-ppg-industries-netflix-and-united-airlines-for-options-opportunity-ahead-of-earnings?source=feed_sector_healthcare
Apr 15, 2024 - This article discusses a recent report from BoFA Securities on US equity options and positioning for potential earnings surprises.
0
Page 1>